Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBT Margin (2016 - 2025)

Historic EBT Margin for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to 17.69%.

  • Haemonetics' EBT Margin rose 33700.0% to 17.69% in Q4 2025 from the same period last year, while for Dec 2025 it was 17.23%, marking a year-over-year increase of 52400.0%. This contributed to the annual value of 15.58% for FY2025, which is 39800.0% up from last year.
  • According to the latest figures from Q4 2025, Haemonetics' EBT Margin is 17.69%, which was up 33700.0% from 15.67% recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' EBT Margin peaked at 21.4% during Q1 2025, and registered a low of 12.17% during Q2 2021.
  • Over the past 5 years, Haemonetics' median EBT Margin value was 13.02% (recorded in 2023), while the average stood at 10.88%.
  • In the last 5 years, Haemonetics' EBT Margin plummeted by -213800bps in 2021 and then skyrocketed by 179600bps in 2022.
  • Quarter analysis of 5 years shows Haemonetics' EBT Margin stood at 8.3% in 2021, then soared by 67bps to 13.83% in 2022, then fell by -5bps to 13.09% in 2023, then rose by 9bps to 14.32% in 2024, then increased by 24bps to 17.69% in 2025.
  • Its last three reported values are 17.69% in Q4 2025, 15.67% for Q3 2025, and 14.05% during Q2 2025.